CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: June 7, 2017
Result type: Reports
Project Number: SR0515-000
Product Line: Reimbursement Review

Generic Name: Evolocumab

Brand Name: Repatha

Manufacturer: Amgen Canada Inc.

Therapeutic Area: Primary hyperlipidemia and mixed dyslipidemia

Indications: Primary hyperlipidemia and mixed dyslipidemia

Submission Type: Resubmission

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: November 22, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions